Leukocyte News and Research

RSS

Simple supplement could reduce heart disease in individuals born with low birth weight

A simple supplement could be a safe and cost-effective way of reducing heart disease in individuals born with a low birth weight, suggests research from the University of Cambridge. The study, carried out in rats, also raises the possibility of developing a blood test to indicate how much damage there is in the aortas of these individuals.

10 Dec 2014

Combination therapy benefits patients with acute myeloid leukemia

Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.

8 Dec 2014

Adolescent and young adult patients with ALL fare better with high-intensity pediatric protocols

Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients--aged 16 to 39 with acute lymphoblastic leukemia (ALL)--tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.

8 Dec 2014

New type of cancer therapy shows promise in patients with advanced leukemia

A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial. The study, led by Eytan M. Stein, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, was presented today at the 56th Annual Meeting of the American Society of Hematology.

8 Dec 2014

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

AbbVie presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML). AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can crowd out healthy blood cells.

8 Dec 2014

Novel targeted therapies and treatment combinations for leukemia

Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

A therapy that liberates the immune system to attack cancer cells drove Hodgkin lymphoma (HL) into complete or partial remission in fully 87 percent of patients with resistant forms of the disease who participated in an early-phase clinical trial, investigators at Dana-Farber Cancer Institute and partnering institutions report in a study published today in the New England Journal of Medicine and simultaneously presented at the annual meeting of the American Society of Hematology in San Francisco.

7 Dec 2014

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Massage therapy: A natural way to strengthen the immune system this flu season

As seasons change our bodies become more susceptible to cold and flu. Massage therapy is a natural way to strengthen the immune system at this vulnerable time, especially if it is already weakened by stress, fatigue or poor nutrition.

4 Dec 2014

BeyondSpring Pharmaceuticals plans to initiate Plinabulin Phase 3 pivotal trial in NSCLC patients

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it plans to initiate a Phase 3 pivotal trial of lead product candidate, Plinabulin, in patients with non-small cell lung cancer (NSCLC) in the first quarter of 2015.

4 Dec 2014

HIV's ability to cause AIDS is declining, finds new research

The rapid evolution of HIV, which has allowed the virus to develop resistance to patients' natural immunity, is at the same time slowing the virus's ability to cause AIDS, according to new research funded by the Wellcome Trust.

2 Dec 2014

Co-enzyme Q supplement lowers age-associated damage that leads to heart disease

New research involving rats, and published in the December 2014 issue of The FASEB Journal, suggests that if you were born at a low birth weight, supplemental co-enzyme Q (CoQ) may lower your risk for heart disease.

2 Dec 2014

U of T professor wins GSK's 2014 Discovery Fast Track Challenge devoted for cancer research

University of Toronto (U of T) Professor Tania Watts is a winner of GSK's 2014 Discovery Fast Track Challenge, which is designed to accelerate the translation of academic research into novel therapies.

2 Dec 2014

Component of Glycyrrhiza uralensis plant may thwart development of metabolic disorders

New research published in the December 2014 issue of the Journal of Leukocyte Biology, shows that a component found in in the plant, Glycyrrhiza uralensis, may inhibit the development of metabolic disorders by stopping the activation of NLRP3, a protein involved in the disease process.

2 Dec 2014

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

Pharmacyclics, Inc.today announced the acceptance of a Type II variation application for IMBRUVICA (ibrutinib) by the European Medicines Agency.

1 Dec 2014

New vaccine shows promise in patients with metastatic breast cancer

A breast cancer vaccine developed at Washington University School of Medicine in St. Louis is safe in patients with metastatic breast cancer, results of an early clinical trial indicate. Preliminary evidence also suggests that the vaccine primed the patients' immune systems to attack tumor cells and helped slow the cancer's progression.

1 Dec 2014

New cell therapy offers hope for patients with liver cirrhosis

Liver disease patients could be helped by a new cell therapy to treat the condition.

24 Nov 2014

BerGenBio's BGB324 gets orphan-drug designation from FDA for AML treatment

BerGenBio AS, an oncology biopharmaceutical company, today announces that the US Food and Drug Administration has granted orphan-drug designation for BGB324 for treatment of acute myeloid leukaemia (AML).

19 Nov 2014

Discovery opens up new routes to strengthen anti-smoking efforts to control TB

TB is an infectious disease that kills 1.5 million people each year, and smoking is the biggest driver of the global TB epidemic. Medical scientists at Trinity College Dublin and St James's Hospital in Ireland have unlocked the mechanism underlying the connection between smoking and Tuberculosis (TB).

17 Nov 2014

Solgar voluntarily recalls ABC Dophilus Powder

Solgar, Inc., of Leonia, NJ, is voluntarily recalling ABC Dophilus Powder. The recall was initiated, out of an abundance of caution, because the product was found to contain Rhizopus oryzae, which may cause Mucormycosis.

16 Nov 2014

Leukocyte News and Research

Simple supplement could reduce heart disease in individuals born with low birth weight

Combination therapy benefits patients with acute myeloid leukemia

Adolescent and young adult patients with ALL fare better with high-intensity pediatric protocols

New type of cancer therapy shows promise in patients with advanced leukemia

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

Novel targeted therapies and treatment combinations for leukemia

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Massage therapy: A natural way to strengthen the immune system this flu season

BeyondSpring Pharmaceuticals plans to initiate Plinabulin Phase 3 pivotal trial in NSCLC patients

HIV's ability to cause AIDS is declining, finds new research

Co-enzyme Q supplement lowers age-associated damage that leads to heart disease

U of T professor wins GSK's 2014 Discovery Fast Track Challenge devoted for cancer research

Component of Glycyrrhiza uralensis plant may thwart development of metabolic disorders

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

New vaccine shows promise in patients with metastatic breast cancer

New cell therapy offers hope for patients with liver cirrhosis

BerGenBio's BGB324 gets orphan-drug designation from FDA for AML treatment

Discovery opens up new routes to strengthen anti-smoking efforts to control TB

Solgar voluntarily recalls ABC Dophilus Powder

Immunology eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News